Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Lymphoma, Large B-Cell, Diffuse 413Lymphoma 401Lymphoma, Non-Hodgkin 337Leukemia, Lymphocytic, Chronic, B-Cell 302Lymphoma, Follicular 295Lymphoma, Mantle-Cell 225Lymphoma, B-Cell, Marginal Zone 159Leukemia 119Lymphoma, B-Cell 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 83Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 39Multiple Myeloma 26Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Dendritic Cell Sarcoma, Interdigitating 22Hematologic Neoplasms 21Leukemia, Hairy Cell 20Intraocular Lymphoma 17Leukemia, Prolymphocytic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Neoplasms, Plasma Cell 13Lymphoproliferative Disorders 12Hematologic Diseases 12

Interventions

Temozolomide 3XENP 1595 2Trastuzumab 2Sodium Chloride 2Dexmedetomidine 2Cancer Vaccines 2Adjuvants, Immunologic 2veliparib 1tucatinib 1tipifarnib 1sagopilone 1pembrolizumab 1interferon gamma-1b 1glutathione pegylated liposomal doxorubicin 1elacestrant 1abemaciclib 1Saline Solution 1Rituximab 1Radiotherapy 1Radiation 1RAD1901 1Oncolytic Virotherapy 1Interferon-gamma 1Immunotherapy 1Dasatinib 1Craniotomy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Central Nervous System Diseases × Rituximab × Clear all
NCT01596127 2018-05-24

Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 7 charts
CNSOther hematologic neoplasm

Central Nervous System Diseases, Leukemia, Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡